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Abstract
Background: The current paradigm describing asthma pathogenesis recognizes the
central role of abnormal epithelial function in the generation and maintenance of
the disease. However, the mechanisms responsible for the initiation of airway
remodeling, which contributes to decreased lung function, remain elusive. There-
fore, we aimed to determine the role of altered pulmonary gene expression in
disease inception and identify proremodeling mediators.
Methods: Using an adenoviral vector, we generated mice overexpressing smad2, a
TGF-b and activin A signaling molecule, in the lung. Animals were exposed to
intranasal ovalbumin (OVA) without systemic sensitization.
Results: Control mice exposed to inhaled OVA showed no evidence of pulmonary
inflammation, indices of remodeling, or airway hyper-reactivity. In contrast, local
smad2 overexpression provoked airway hyper-reactivity in OVA-treated mice,
concomitant with increased airway smooth muscle mass and peribronchial colla-
gen deposition. Pulmonary eosinophilic inflammation was not evident, and there
was no change in serum IgE or IgG1 levels. The profound remodeling changes
were not mediated by classical pro-inflammatory Th2 cytokines. However, uric
acid and interleukin-1b levels in the lung were increased. Epithelial-derived endo-
thelin-1 and fibroblast growth factor were also augmented in smad2-expressing
mice. Blocking endothelin-1 prevented these phenotypic changes.
Conclusions: Innate epithelial-derived mediators are sufficient to drive airway
hyper-reactivity and remodeling in response to environmental insults in the
absence of overt Th2-type inflammation in a model of noneosinophilic, nonin-
flammed types of asthma. Targeting potential asthma therapies to epithelial cell
function and modulation of locally released mediators may represent an effective
avenue for therapeutic design.
Asthma is a complex multifactorial inflammatory disease
characterized by airway hyper-responsiveness (AHR) in
response to a wide variety of inhaled environmental antigens.
Structural changes to the airway wall collectively termed ‘air-
way remodeling’ contribute to airway dysfunction and, ulti-
mately, provoke clinical symptoms. It has been proposed
that the airway epithelium is central to the development of
disease (1). Airway remodeling encompasses increased deposi-
tion of subepithelial extracellular matrix (ECM) proteins,
increased smooth muscle mass, goblet cell hyperplasia, and
angiogenesis (2). However, the relationship between inflam-
mation and remodeling remains unclear, as remodeling
occurs early in disease pathogenesis and is not affected by
steroid therapy (3). Pharmacologically induced bronchocon-
striction has been shown to promote airway remodeling in
asthmatics without enhancing inflammation (4), implying that
remodeling can be dissociated from inflammation. However,
as all patients examined were atopic asthmatics, they have an
inflammatory phenotype. In mice, adenoviral-mediated epi-
thelial overexpression of smad2, a TGF-b and activin A sig-
naling molecule, potentiates remodeling and AHR, without
exacerbating the eosinophilia and Th2 inflammation in
response to the common aeroallergen, house dust mite (5).
Phosphorylated smad2 is increased following allergen
challenge and is overexpressed in asthmatic patients, correlat-
ing with increased deposition of ECM (6, 7). Moreover, the
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closely related gene smad3 has recently been identified as an
asthma susceptibility gene in a large-scale genome-wide asso-
ciation study (8).
To dissect the effect of altered epithelial gene expression
on the development of airway remodeling without the con-
founding influence of concurrent inflammation, we investi-
gated the pulmonary response to inhaled ovalbumin (OVA),
a commonly used surrogate allergen that normally promotes
mucosal tolerance in mice if inhaled in the absence of sys-
temic sensitization (9). OVA-exposed mice overexpressing
epithelial smad2 secrete airway smooth muscle (ASM) mito-
gens, including endothelin-1, fibroblast growth factor (FGF),
and the innate signaling molecules IL-1b and uric acid,
resulting in AHR and airway remodeling in the absence of
eosinophilic or Th2-type inflammation. These data suggest
that a single alteration in the gene expression profile of the
airway epithelium can completely alter the pulmonary
response to a normally innocuous aeroallergen. Our observa-
tions give credence to the idea that mucosally derived media-
tors can drive airway remodeling and AHR independent of
inflammation in the context of altered epithelial gene expres-
sion. Moreover, epithelial cells are firmly established as
master regulators, which can dictate the threshold at which
immune responses to inhaled stimuli are initiated.
Methods
Female BALB/c mice (Charles River, Margate, UK), 6–
8 weeks old received either 15 lg OVA (0.5 mg/ml) (Sigma-
Aldrich, Dorset, UK) or 30 ll of vehicle, PBS, intranasally
3 days a week for up to 3 weeks. Selected groups received a
first-generation replication-deficient adenovirus serotype 5
containing murine smad2 cDNA (AdS) (2 9 109 viral pfu in
25 ll PBS) or a control mock vector (AdC) 2 days prior to
commencing instillation of either OVA or PBS (5). In addition,
mice received either endothelin antagonist PD 142893 (Sigma,
Dorset, UK) or vehicle control (PBS) via injection prior (i.p.)
to intranasal challenge with OVA or PBS. All experiments were
performed in accordance with UK Home Office guidelines.
Airway responsiveness was determined by direct measure-
ments of resistance (RI) and compliance (Cdyn) in anesthe-
tized and tracheostomized mice (5). Selected groups received
salbutamol (2 lg in PBS i.n., Sigma) 20 min prior to mea-
surement of lung function and 24 h postfinal OVA challenge.
Serum, bronchoalveolar lavage (BAL), lung tissue, and
lung cells were collected (5). Differential cell counts were
carried out on Wright–Giemsa-stained cytospins. Paraffin-
embedded sections (4 lm) were stained with hematoxylin/
eosin (H&E), periodic acid-Schiff (PAS), and Sirus Red. All
scoring and measurements were performed on medium air-
ways measuring 150–250 lm in diameter. Paraffin sections
were stained with rabbit anti-mouse proliferating cell nuclear
antigen (PCNA) (Abcam, Cambridge, UK), a-smooth muscle
actin (a-SMA) (Abcam), FGF-2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), P-smad2 (S465/467) (Cell Signaling
Technology, Danvers, MA, USA), or endothelin (BiossInc,
Woburn, CA, USA) using an avidin/biotin staining method.
Recently synthesized acid-soluble collagen was measured in
the lung by biochemical assay (Sircol collagen assay; Biocol-
or, Belfast, UK) and normalized for tissue weight.
Lung tissue supernatant was analyzed by ELISA using IL-
4, IL-5, IFN-c (PharMingen, Oxford, UK), IL-33, IL-25
(R&D systems, Abingdon, UK), IL-1a and IL-1b (active
forms), IL-6 (eBioscience, Hatfield, UK), endothelin (Enzo
Life Sciences, Exeter, UK), and IL-13 kits (R&D systems).
Uric acid was measured using Amplex red uric acid/uricase
assay kit (Invitrogen, Paisley, UK). All data were normalized
for lung weight. Paired antibodies for IgE and IgG1 (R&D
systems) were used to measure serum Ig levels.
Disaggregated lung cells were stained with CD3, CD4, and
ST2 or relevant isotype controls for 20 min at 4°C. Fixed
cells were analyzed on a FACSCalibarTM using CellQuest
(BD Biosciences, Oxford, UK).
Additional details on the methods utilized in this study are
provided in the Supporting Information (Data S1).
Data were analyzed using Prism 4 (GraphPad software
Inc., La Jolla, CA, USA). Multiple comparisons were per-
formed using Kruskal–Wallis test. A two-tailed P value was
determined by the Mann–Whitney U-test when comparing
between two groups. Data shown represent means  SEM of
at least two independent experiments (n = 6–12).
Results
Local smad2 overexpression promotes AHR in response to
inhaled OVA in the absence of pulmonary inflammation
Intranasal instillation of OVA in na€ıve BALB/c mice leads
to immunological tolerance (9). In this study, we evaluated
how altered expression of smad2 in the lung affects the
pulmonary responses to inhaled OVA. We have shown
previously that administration of the control adenoviral vec-
tor (AdC) or virus containing the transgene smad2 (AdS)
results in gene expression localized primarily in epithelial
cells of the conducting airways and does not itself initiate
an inflammatory response in the lung (5). Therefore, in all
experiments described here, AdC was used as an appropri-
ate control. Overexpression of smad2 had no effect on base-
line AHR. However, AdS mice exposed to OVA showed
significantly increased airway resistance and decreased com-
pliance in response to methacholine when compared with
PBS-treated mice or the AdC OVA group (Fig. 1A,B).
Asthma is often characterized by eosinophilic inflammation.
However, there was no evidence of pulmonary inflammation
in any of the groups of mice (Fig. 1C). Quantitatively there
were no significant differences in the total number of leuko-
cytes or eosinophils recovered from the lung (Fig. 1D,E) or
BAL fluid (data not shown) in mice exposed to intranasal
OVA compared with PBS. Similarly, levels of eotaxin were
comparable between all groups (Fig. 1F). There was no
difference in Th2 cell numbers in the OVA-treated mice
compared with PBS controls (Fig. 1G). Likewise, serum
total IgE and IgG1 were not modulated (Fig. 1H). OVA-
specific IgE and IgG1 were also not detectable (data not
shown). Mucosal OVA-specific IgA levels were slightly
increased in the BALF of OVA-treated mice; however, there
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was no difference comparing AdC OVA with AdS OVA
mice (data not shown). Thus, altered epithelial smad2
expression influences the development of AHR after OVA
challenge, but does not initiate an overt pulmonary inflam-
matory reaction.
Inhaled OVA exposure activates airway epithelial cells and
induces collagen deposition in mice overexpressing smad2
Epithelial PAS staining for mucous was absent from lungs of
all treatment groups (Fig. 2A), indicating there was no
Figure 1 Ovalbumin (OVA) exposure results in airway hyper-
responsiveness (AHR) in the absence of inflammation in mice over-
expressing smad2 in the airway epithelium. (A) Resistance and (B)
compliance measured in tracheotomized animals in response to
increasing doses of methacholine. (C) Lung sections stained with
H&E. Original magnification 940. Scale bar = 50 lm. Representa-
tive photomicrographs are shown. (D) Total cells recovered from
lung tissue. (E) Eosinophils determined by differential counting of
cytospins prepared from the lung digest. (F) Eotaxin levels in the
lung as determined by ELISA (assay sensitivity 3 pg/ml). (G)
CD4+T1ST2+ Th2 cells recovered from the lung and quantified by
flow cytometry. (H) Serum total IgE and IgG1 levels measured by
ELISA (assay sensitivity 2 ng/ml and 80 pg/ml, respectively). Data
shown represent means  SEM (N = 6–18) of at least two inde-
pendent experiments. *P < 0.05 compared with PBS-treated
groups or OVA-exposed AdC mice.
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change to a mucous-secreting phenotype. Interestingly,
however, there was an increase in the number of PCNA+
epithelial cells (Fig. 2B,C). PCNA is expressed by
S-phase-proliferating cells suggesting that despite the absence
of mucus hyperplasia, the airway epithelium of the AdS
OVA-exposed mice is in an activated state.
PBS-treated mice demonstrated minimal collagen staining
around the airways. In contrast, mice overexpressing smad2
and exposed to OVA showed a notable increase in the deposi-
tion of collagen compared with PBS-treated or the AdC OVA
mice (Fig. 2D). Recently synthesized total lung collagen was
increased in the AdS OVA mice (Fig. 2E), reflecting the spe-
cific increase in peribronchiolar collagen density (Fig. 2F).
Inhaled OVA exposure increases ASM mass and contractility
in AdS mice
Lung sections were immunostained with a-SMA to identify
myofibroblasts and smooth muscle cells. Discontinuous
a-SMA+ cells were observed in the PBS-treated groups and
Figure 2 Airway remodeling induced by ovalbumin (OVA) in epithe-
lial smad2-overexpressing mice. (A) Lung sections stained with
periodic acid-Schiff (PAS) to identify mucin-containing (purple) cells.
(B) Lung sections stained with antibody to proliferating cell nuclear
antigen (PCNA, brown staining). (C) Quantitation of PCNA+ airway
epithelial cells. (D) Sirius Red staining of lung sections depicts peri-
bronchiolar and perivascular collagen (red). (E) Recently synthesized
total lung collagen was quantified by a biochemical (Sircol) assay.
(F) Quantitative image analysis of subepithelial peribronchiolar colla-
gen density determined by measuring Sirius Red-stained collagen
in lung sections under polarized light. Original magnification 940.
Scale bar = 50 lm. Representative photomicrographs are shown.
Data shown represent means  SEM (N = 6–12) of two indepen-
dent experiments. *P < 0.05 compared with PBS-treated groups or
OVA-exposed AdC mice.
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AdC OVA mice. In contrast, a continuous layer of peribron-
chiolar a-SMA+ cells was quantified in the AdS OVA mice
(Fig. 3A,B). The extent of ASM hyperplasia was determined
by calculating the percentage of PCNA+ subepithelial cells.
This index of cellular proliferation was increased in the AdS
OVA group compared with PBS controls and AdC OVA-
treated mice (Fig. 3C,D).
The b2-adrenoceptor agonist, salbutamol, blocked the
increase in airway resistance in the OVA-exposed mice over-
expressing smad2 (Fig. 3E), demonstrating a pivotal role of
smooth muscle contraction in the alteration of lung func-
tion. In contrast, the decreased airway compliance was not
reversed (Fig. 3F). To confirm that the observed proremod-
eling effects in the AdS OVA mice were not solely due to
contamination of the OVA preparation by bacterial-derived
endotoxins, we utilized endograde OVA, which contains
<1 EU LPS/mg. An identical phenotype was observed in
the AdS endograde OVA mice as the AdS OVA mice
(Fig. S1).
Mediators of airway remodeling
We measured levels of the pro-inflammatory cytokines IL-1a,
IL-6, and IL-33; Th2 cytokines IL-4, IL-5, IL-13, and IL-25;
the Th1 cytokine IFN-c; and the pleiotropic growth factor
TGF-b in the lung and BALF. However, no differences in
the levels of any of the mediators tested were observed
between groups at either week 1, prior to the onset of remod-
eling changes and development of AHR, or at week 3 when
AHR and remodeling are established (Table S1).
Figure 3 Airway smooth muscle changes induced by ovalbumin
(OVA) in AdS mice. (A) Lung sections stained with an antibody
against a-smooth muscle actin (a-SMA, brown staining), depicting
myofibroblasts and smooth muscle cells. (B) Quantification of
a-SMA+ peribronchiolar area. (C) Lung sections stained with an
antibody against proliferating cell nuclear antigen (PCNA, brown
staining). (D) Quantitation of PCNA+ peribronchiolar mesenchymal
cells. Original magnification 940. Scale bar = 50 lm. Representa-
tive photomicrographs are shown. (E) Airway resistance and (F)
compliance measured in tracheotomized animals in response to
increasing doses of methacholine. Data shown represent
means  SEM (N = 4–12) of two independent experiments.
*P < 0.05 compared with PBS-treated groups or OVA-exposed AdC
mice. †P < 0.05 comparing AdS OVA-challenged mice treated with
salbutamol or vehicle, PBS.
Allergy 68 (2013) 1579–1588 © 2013 The Authors. Allergy published by John Wiley & Sons Ltd 1583
Gregory et al. Bronchial epithelium directs airway remodeling
Innate epithelial mediators are increased in AdS OVA mice
To investigate the mechanism by which altered pulmonary
gene expression affects AHR and remodeling, we measured
levels of mediators associated with innate immune signaling.
Endothelin-1 is a potent bronchoconstrictor peptide with
growth-promoting properties (10). Endothelin-1 is produced
by airway epithelial cells (Fig. 4A), and increased levels of
this mediator are released into the airways of AdS OVA
mice (Fig. 4B). Increased expression of epithelial-derived
FGF was also observed in these mice (Fig. 4C,D). Pulmo-
nary levels of IL-1b (Fig. 4E) and the damage-associated
molecular pattern, uric acid (Fig. 4F), were also significantly
increased. Increased levels of these mediators were detected
as early as 1 week following initial OVA challenge
(Fig. S2).
Blocking endothelin abrogates airway remodeling and AHR
To determine whether endothelin has a role in driving the
observed airway remodeling, AdS OVA mice were treated
with the nonselective endothelin receptor antagonist PD
142893 (Fig. 5). Endothelin receptor blockade prevented the
OVA-induced AHR (Fig. 5A,B), associated collagen deposi-
tion (Fig. 5C,D) and ASM hyperplasia (Fig. 5E,F). Although
pulmonary endothelin levels were unaffected by antagonism
of its receptor (Fig. 5G), the downstream effectors, uric acid,
IL-1b, and FGF, were reduced to baseline in the PD 142893-
treated AdS OVA mice (Fig. 5H–J).
Discussion
Airway remodeling is a recognized feature of the asthmatic
lung, and the epithelium is a prominent source of ECM com-
Figure 4 Ovalbumin (OVA) increases mediators of airway remodel-
ing and airway hyper-responsiveness (AHR) in mice overexpressing
smad2 in the airway epithelium. (A) Endothelin-1 expression (red-
stained) in airway epithelial cells correlates with (B) endothelin-1 lev-
els in the BALF (assay sensitivity 0.41 pg/ml). (C) Lung sections
stained with an antibody against fibroblast growth factor (FGF, brown
staining). (D) Pulmonary FGF-2 levels. (E) Pulmonary IL-1b (assay
sensitivity 8 pg/ml) and (F) uric acid levels (assay sensitivity 100 nM).
Representative photomicrographs are shown. Original magnification
940. Scale bar = 50 lm. Data shown represent means  SEM
(N = 6–18) of at least two independent experiments. *P < 0.05
compared with PBS-treated groups or OVA-exposed AdC mice.
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Figure 5 Airway remodeling and airway hyper-responsiveness
(AHR) are driven by endothelin-1 and uric acid. (A) Resistance and
(B) compliance measured in tracheotomised animals in response to
increasing doses of methacholine. (C) Quantitative image analysis
of subepithelial peribronchiolar collagen density determined by
measuring Sirius Red-stained collagen in lung sections under polar-
ized light. (D) Recently synthesized total lung collagen was quanti-
fied by a biochemical (Sircol) assay. (E) Quantification of a-smooth
muscle actin (a-SMA)+ peribronchiolar area. (F) Quantitation of pro-
liferating cell nuclear antigen (PCNA)+ peribronchiolar mesenchymal
cells. (G) Pulmonary endothelin-1, (H) uric acid, (I) IL-1b, and (J)
fibroblast growth factor-2 (FGF-2) levels. Data shown represent
means  SEM (N = 6–12) of two independent experiments.
*P < 0.05 compared with PBS-treated groups or ovalbumin (OVA)-
exposed AdC mice. †P < 0.05 comparing AdS OVA-challenged
mice treated with PD142893 to AdS OVA PBS.
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ponents and fibrogenic mediators. However, the mechanisms
responsible for remodeling and the relative contribution of
the bronchial epithelium in this process are still poorly
understood. Local smad2 overexpression resulted in
enhanced AHR and airway remodeling in response to intra-
nasal OVA challenge. Despite the pronounced effects on lung
function and remodeling, there was no evidence of eosino-
philia or increased Th2 cells within the lung. Additionally,
there was no change in the levels of Th2-associated cytokines,
and no effect on B-cell responses as serum levels of IgE and
IgG1 were not increased in AdS mice compared with AdC
control groups irrespective of OVA challenge. Instead AHR
and remodeling was associated with the specific induction of
epithelial-derived smooth muscle mitogens.
Asthma is heterogeneous with respect to clinical features
(11, 12), and Th2-type inflammation is characteristic only in
a proportion of patients. Paucigranulocytic asthma is a phe-
notype with little or no inflammation based on the cellular
composition of induced sputum samples. Multivariate cluster
approaches to phenotyping asthma have also identified a dis-
tinct group of female asthmatics with a preponderance of
obesity and lack of eosinophilia (11). Additionally, airway
remodeling in pediatric severe therapy-resistant asthma has
recently been shown not to correlate with Th2 cytokines (13).
Animal models allow dissection of mechanistic pathways,
which may be important in driving disease pathology.
Although the model presented here does not represent a model
of clinical disease, it provides a vehicle for the study of remod-
eling in the absence of underlying inflammation. Using this
approach, we show unequivocally that AHR and remodeling
driven by altered pulmonary gene expression can develop inde-
pendently of eosinophilia or T-cell recruitment, which is
impossible to do in human subjects. In the context of altered
gene expression, exposure to a usually innocuous stimulus
results in epithelial-derived innate mediator release, which pro-
motes airway remodeling and AHR. Intrinsic abnormalities of
epithelial cells, ASM contractility, or remodeling may provide
a mechanism for noninflammatory/Th2-low asthma.
Pretreatment of mice with salbutamol abrogates the
increased airway resistance in AdS OVA-challenged mice,
suggesting that the enhanced resistance is mainly due to
increased contractility of smooth muscle. In contrast, the
decrease in pulmonary compliance is likely due to the
increased peribronchiolar collagen deposition, and the con-
ducting airways remain ‘stiff’ due to excess ECM, which has
previously been associated with a decline in lung function in
asthmatic patients and the loss of bronchodilator reversibility
(10, 14). Treatment of AdS OVA mice with the endothelin
antagonist prevents the increase in peribronchiolar collagen
deposition and associated reduction in airway compliance.
Endothelins promote synthesis of ECM proteins by
epithelial cells and fibroblasts, myofibroblast differentiation,
and proliferation of mesenchymal cells (15, 16). They have
also been implicated in the generation of AHR (17, 18).
Levels of endothelin-1 were increased in AdS OVA-treated
mice and correlate with the observed increase in peribron-
chiolar ASM mass and collagen deposition. Increased levels
of endothelin-1 are also detected in the BAL fluid and
serum from severe asthmatics, particularly those with steroid
refractory asthma, and correlate with increased ASM area
(19, 20). Endothelin receptors are expressed on fibroblasts
and myofibroblasts (21), and endothelin-1 can both promote
fibrogenesis and decrease myofibroblast susceptibility to
apoptosis (22). FGF has been shown to directly stimulate
proliferation and migration of ASM cells in vitro (23), and
there is data to support its role as an ASM mitogen in
human asthma (24). Endothelin-1 has previously been
shown to increase FGF-2 expression in vitro (25), and here
we show increased pulmonary FGF-2 in AdS OVA mice.
Endothelin receptor blockade prevented the AHR and
airway remodeling in AdS OVA mice. These data suggest
that activation of airway epithelium leads to secretion of
endothelin-1 and FGF-2 with subsequent proliferation of
ASM cells and secretion of ECM.
Airway remodeling and AHR correlated with increases in
pulmonary IL-1b, a pro-inflammatory cytokine involved in
the pathogenesis of asthma that can induce AHR (25, 26).
Asthmatic epithelia grown at air–liquid interface secrete more
basolateral IL-1b following epithelial injury than cells derived
from nonasthmatics (27). In vitro studies using human cor-
neal and intestinal epithelial cell monolayers have shown that
IL-1b decreases transepithelial resistance and increases
permeability resulting in redistribution of tight junction pro-
teins (28, 29). Similar perturbations of the airway epithelium
have been suggested to drive the genesis of asthma (30).
IL-1b is produced by cleavage of an inactive pro-IL-1b pre-
cursor by autocleavage of caspase-1, a protease activated by
NLRP3 inflammasomes (31). Human airway epithelial cells
respond to particulate matter by increasing NLRP3 inflam-
masome-mediated IL-1b production (32). Intracellular
NLRP3 senses endogenous danger signals such as uric acid,
resulting in inflammasome activation (33). Hyperuricemia is
associated with myocardial hypertrophy and remodeling
mediated via an endothelin-1 pathway (34). The current data
suggest that a similar uric acid–endothelin-1 axis may operate
in the lung to promote fibrosis as increased uric acid levels
were observed in the lungs of AdS OVA mice. The levels of
endothelin-1, uric acid, and IL-1b were increased as early as
7 days following the first OVA challenge, prior to the onset
of remodeling changes. This is perhaps not surprising as
innate mediator release from epithelial cells does not require
elements of the adaptive immune system and epithelial cells
respond rapidly to ‘danger’ signals, particularly in the AdS
OVA mice, which have an altered epithelial phenotype.
It may seem surprising that there was no observable neu-
trophilia despite increases in IL-1b and uric acid. Although
significant, the increase in both of these mediators was rela-
tively small compared with levels previously reported in
other models of allergic airway diseases (35). It is plausible
that there is a threshold for inflammatory mediators, which
must be reached to promote a systemic inflammatory
response and recruitment of cells from the blood and bone
marrow. In contrast, small increases in endothelin-induced
IL-1b and uric acid acting locally at the mucosal surface, at
least in association with altered pulmonary gene expression,
are sufficient to promote extreme changes in the bronchial
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architecture where the threshold for a remodeling response
is lowered.
Although the exact mechanism by which OVA induces
pathophysiology in the Ads OVA mice remains enigmatic,
other examples of non-receptor-mediated signaling have been
described. Hypoxia increases TGF-b signaling and sub-
sequently endothelin-1 resulting in pulmonary remodeling
(36). Similarly, inhaled asbestos and silica also cause lung
damage without binding to receptors on pulmonary cells.
Pertinent to our study, the downstream effects of both these
environmental insults are mediated via IL-1b (37). Conceiv-
ably instilled OVA may be endocytosed by airway epithelial
cells, as demonstrated in cultured 16HBE cells. We have
demonstrated an increase in smad2 phosphorylation only in
OVA-exposed mice overexpressing epithelial smad2 (Fig. S3).
In mice with perturbed epithelial gene expression, this is suf-
ficient stimulus to induce innate smad-mediated increases in
endothelin-1 synthesis and subsequently the initiation of
remodeling changes.
Thus, even relatively innocuous antigens such as OVA
can trigger innate immune pathways and promote pro-
found remodeling changes in the lung in the context of
susceptible airway epithelium. These data consolidate the
central role of the epithelium in determining the response
of the lung to environmental airway challenge. Successful
development of therapeutics to target mucosally derived
mediators would likely be of particular benefit to patients
with noneosinophilic, noninflammed types of asthma where
current treatments, aimed at modulating inflammation and
IgE, are ineffective at modulating AHR and airway
remodeling.
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